Novel Insights Into Mesothelioma Therapy : Emerging Avenues and Future Prospects
Copyright © 2022 Kuryk, Rodella, Staniszewska, Pancer, Wieczorek, Salmaso, Caliceti and Garofalo..
Malignant mesothelioma is a rare and aggressive cancer that develops in the thin layer surrounding the mesothelium and is mainly caused by asbestos exposure. Despite improvements in patient prognosis with conventional cancer treatments, such as surgery, chemotherapy, and radiotherapy, there are still no curative treatment modalities for advanced disease. In recent years, new therapeutic avenues have been explored. Improved understanding of the mechanisms underlying the dynamic tumor interaction with the immune system has led to the development of immunotherapeutic approaches. Numerous recent clinical trials have shown a desire to develop more effective treatments that can be used to fight against the disease. Immune checkpoint inhibitors, oncolytic adenoviruses, and their combination represent a promising strategy that can be used to synergistically overcome immunosuppression in the mesothelioma tumor microenvironment. This review provides a synthesized overview of the current state of knowledge on new therapeutic options for mesothelioma with a focus on the results of clinical trials conducted in the field.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Frontiers in oncology - 12(2022) vom: 01., Seite 916839 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kuryk, Lukasz [VerfasserIn] |
---|
Links: |
---|
Themen: |
Combination therapy |
---|
Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3389/fonc.2022.916839 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM343059452 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM343059452 | ||
003 | DE-627 | ||
005 | 20231226204931.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fonc.2022.916839 |2 doi | |
028 | 5 | 2 | |a pubmed24n1143.xml |
035 | |a (DE-627)NLM343059452 | ||
035 | |a (NLM)35785199 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kuryk, Lukasz |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel Insights Into Mesothelioma Therapy |b Emerging Avenues and Future Prospects |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2022 Kuryk, Rodella, Staniszewska, Pancer, Wieczorek, Salmaso, Caliceti and Garofalo. | ||
520 | |a Malignant mesothelioma is a rare and aggressive cancer that develops in the thin layer surrounding the mesothelium and is mainly caused by asbestos exposure. Despite improvements in patient prognosis with conventional cancer treatments, such as surgery, chemotherapy, and radiotherapy, there are still no curative treatment modalities for advanced disease. In recent years, new therapeutic avenues have been explored. Improved understanding of the mechanisms underlying the dynamic tumor interaction with the immune system has led to the development of immunotherapeutic approaches. Numerous recent clinical trials have shown a desire to develop more effective treatments that can be used to fight against the disease. Immune checkpoint inhibitors, oncolytic adenoviruses, and their combination represent a promising strategy that can be used to synergistically overcome immunosuppression in the mesothelioma tumor microenvironment. This review provides a synthesized overview of the current state of knowledge on new therapeutic options for mesothelioma with a focus on the results of clinical trials conducted in the field | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a combination therapy | |
650 | 4 | |a immune checkpoint inhibitors | |
650 | 4 | |a immunotherapy | |
650 | 4 | |a mesothelioma | |
650 | 4 | |a oncolytic adenoviruses | |
700 | 1 | |a Rodella, Giulia |e verfasserin |4 aut | |
700 | 1 | |a Staniszewska, Monika |e verfasserin |4 aut | |
700 | 1 | |a Pancer, Katarzyna Wanda |e verfasserin |4 aut | |
700 | 1 | |a Wieczorek, Magdalena |e verfasserin |4 aut | |
700 | 1 | |a Salmaso, Stefano |e verfasserin |4 aut | |
700 | 1 | |a Caliceti, Paolo |e verfasserin |4 aut | |
700 | 1 | |a Garofalo, Mariangela |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 12(2022) vom: 01., Seite 916839 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2022 |g day:01 |g pages:916839 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2022.916839 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2022 |b 01 |h 916839 |